-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
*Only for medical professionals to read for reference, 1 minute a day, to give you professional "talking information" in the tumor circle! (If you need the original text of the literature, you can add the editor WeChat yxj_oncology to obtain) Key points to remind the latest research data: a new first-line treatment plan for advanced NSCLC! Star immune combination: O+Y+ limited chemotherapy regimen, with a 2-year survival rate of 38%.
American Cancer Society (ACS): Nearly half of cancer occurrences and deaths are preventable, mainly related to these factors.
BJ Haem: Family aggregation of early-onset hematological malignancies CLIN CANCER RES: Afatinib VS Afatinib + Cetuximab as the first-line treatment option for EGFR-mutant non-small cell lung cancer (NSCLC) patients (IFCT-1503 ACE-Lung) Phase II randomized trial 01 First-line advanced NSCLC New treatment plan! Star immune combination: O+Y+ limited chemotherapy regimen, with a 2-year survival rate of 38%.
Recently, Bristol-Myers Squibb (BMS) announced anti-PD-1 therapy O drug combined with anti-CTLA-4 therapy Y drug and platinum-containing dual-effect chemotherapy for first-line treatment of advanced stage The latest data from the Phase III CheckMate-9LA study of non-small cell lung cancer (NSCLC).
The results showed that after 2 years of follow-up, 38% of patients were still alive at 2 years, compared with only 26% of patients who received chemotherapy only.
Compared with 4 cycles of chemotherapy alone, O+Y+2 cycles of chemotherapy showed long-lasting survival benefits, with continuous improvement in overall survival (OS) and progression-free survival (PFS), and extended duration of remission (DOR) .
It is worth noting that in the key subgroup of patients, this combination therapy based on dual immunotherapy, whether in terms of PD-L1 expression level or histology, has shown clinical benefits.
02 American Cancer Society (ACS): Nearly half of cancer occurrences and deaths are preventable, mainly related to these factors.
Recently, the authoritative organization American Cancer Society (ACS) issued a report called Cancer Prevention & Early Detection Facts & Figures 2021-2022 The report analyzed the risk factors and preventive measures of cancer incidence and death.
The report shows that 42% of new cancers and 45% of cancer deaths in the United States are related to controllable risk factors.
Screenshot of the report The report pointed out that changeable risk factors such as smoking, overweight or obesity, drinking, lack of exercise, unhealthy diet, ultraviolet radiation, and pathogen infection are the main risk factors for cancer occurrence and death in the United States.
Avoiding risk factors, identifying and removing precancerous lesions through screening, and detecting cancer at an early stage when treatment is more effective will prevent hundreds of thousands of cancers from occurring and dying.
03BJ Haem: Family clustering of early-onset hematological malignancies A few days ago, BJ Haem published a study online.
A significant increase in standardized incidence rate (SIR) indicates that there is a common cause in some families.
In early-onset hematological malignancies Tumor (HM) patients should pay attention to this clinical situation during treatment.
Article release screenshots Few population-based studies of HM family clustering specifically focus on early-onset HM.
The study evaluated individuals diagnosed with early-onset HM and their relatives Hodgkin’s lymphoma (HL), non-Hodgkin’s lymphoma (NHL), acute lymphoblastic leukemia/lymphoma (ALL/LBL) and acute myeloid cells SIR and cumulative risk of AML.
The study identified 8,791 patients ≤40 years of age who were diagnosed with primary HM from the Finnish Cancer Registry between 1970 and 2012, and retrieved 75,774 family members from the population register.
Among the most common children, adolescents, and young adults (AYA) with HM, the SIR of their first-degree relatives, HM, is elevated.
Among them, HL (SIR: 9.
09; 95% CI: 5.
55-14.
04) and AML (SIR: 8.
29, 95% CI: 1.
00-29.
96) have the highest risk.
The cumulative risk of HL is also highest for siblings under 40 (0.
92% vs 0.
11%).
04CLIN CANCER RES: Afatinib VS Afatinib + Cetuximab as the first-line treatment option for EGFR-mutant non-small cell lung cancer (NSCLC) patients (IFCT-1503 ACE-Lung) Phase II randomized trial RES published a study online that showed that for untreated patients with advanced EGFR-mutant non-small cell lung cancer (NSCLC), there is no need for further studies on the addition of cetuximab to afatinib treatment.
Article release screenshots Using tyrosine kinase inhibitors and monoclonal antibodies to double inhibition of EGFR may be a new treatment strategy for non-small cell lung cancer (NSCLC).
We evaluated the efficacy and toxicity of afatinib vs afatinib+cetuximab in the first-line treatment of advanced EGFR-mutant NSCLC.
In this non-comparative, randomized, open-label, phase II study, patients with stage III/IV EGFR-positive NSCLC were randomly assigned (1:1) to receive afatinib (A) or afatinib + cetuximab Anti-(A+C) treatment.
Group A: Afatinib 40 mg orally once a day; Group A+C: Cetuximab 250 mg/m2 was injected intravenously on the 15th day of the first cycle, and then 500 mg/m2 every 2 weeks It is given once for 6 months.
The primary endpoint is the treatment failure rate at 9 months.
In addition, exploratory analysis of EGFR circulating tumor DNA in plasma was also carried out.
From June 2016 to November 2018, 59 patients were enrolled in group A and 58 patients were enrolled in group A+C.
The trial was terminated early due to invalidity analysis.
At 9 months, the proportion of patients without treatment failure in the two groups was similar (59.
3% in group A vs 64.
9% in group A+C), and the median time to treatment failure (TTF) was 11.
1 months (95%CI: 8.
5-14.
1) And 12.
9 (95%CI: 9.
2-14.
5) months.
The other endpoints [Progress-Free Survival (PFS) and Overall Survival (OS)] showed no significant improvement in combination therapy.
Adverse events (≥Grade 3) in the A+C group increased slightly.
The allele frequencies of EGFR gene mutations in circulating tumor DNA at baseline in both treatment groups were associated with shortening of PFS.
Reference: [1] http://news.
bioon.
com/article/6787384.
html[2] American Cancer Society.
Cancer Prevention & Early Detection Facts & Figures, 2021-2022.
Atlanta: American Cancer Society; 2021.
[ 3] Rönkkö R, Hirvonen E, Malila N, Kilpivaara O, Wartiovaara-Kautto U, Pitkäniemi J.
Familial aggregation of early-onset haematological malignancies.
Br J Haematol.
2021 May 18.
doi: 10.
1111/bjh.
17477.
Epub ahead of print.
[4] Cortot AB, Madroszyk-Flandin A, Giroux Leprieur E, Molinier O, Quoix E, Berard H, Otto J, Rault I, Moro-Sibilot D, Raimbourg J, Amour E, Morin F, Hureaux J, Moreau L, Debieuvre D, Morel H, Renault A, Pichon E, Huret B, Charpentier S, Denis MG, Cadranel J.
First-line Afatinib plus Cetuximab for EGFR-mutant Non-small-cell Lung Cancer: Results from the Randomized Phase 2 IFCT-1503 ACE-Lung Study.
Clin Cancer Res.
2021 May 24: clincanres.
4604.
2020.
doi:10.
1158/1078-0432.
CCR-20-4604.
Epub ahead of print.
American Cancer Society (ACS): Nearly half of cancer occurrences and deaths are preventable, mainly related to these factors.
BJ Haem: Family aggregation of early-onset hematological malignancies CLIN CANCER RES: Afatinib VS Afatinib + Cetuximab as the first-line treatment option for EGFR-mutant non-small cell lung cancer (NSCLC) patients (IFCT-1503 ACE-Lung) Phase II randomized trial 01 First-line advanced NSCLC New treatment plan! Star immune combination: O+Y+ limited chemotherapy regimen, with a 2-year survival rate of 38%.
Recently, Bristol-Myers Squibb (BMS) announced anti-PD-1 therapy O drug combined with anti-CTLA-4 therapy Y drug and platinum-containing dual-effect chemotherapy for first-line treatment of advanced stage The latest data from the Phase III CheckMate-9LA study of non-small cell lung cancer (NSCLC).
The results showed that after 2 years of follow-up, 38% of patients were still alive at 2 years, compared with only 26% of patients who received chemotherapy only.
Compared with 4 cycles of chemotherapy alone, O+Y+2 cycles of chemotherapy showed long-lasting survival benefits, with continuous improvement in overall survival (OS) and progression-free survival (PFS), and extended duration of remission (DOR) .
It is worth noting that in the key subgroup of patients, this combination therapy based on dual immunotherapy, whether in terms of PD-L1 expression level or histology, has shown clinical benefits.
02 American Cancer Society (ACS): Nearly half of cancer occurrences and deaths are preventable, mainly related to these factors.
Recently, the authoritative organization American Cancer Society (ACS) issued a report called Cancer Prevention & Early Detection Facts & Figures 2021-2022 The report analyzed the risk factors and preventive measures of cancer incidence and death.
The report shows that 42% of new cancers and 45% of cancer deaths in the United States are related to controllable risk factors.
Screenshot of the report The report pointed out that changeable risk factors such as smoking, overweight or obesity, drinking, lack of exercise, unhealthy diet, ultraviolet radiation, and pathogen infection are the main risk factors for cancer occurrence and death in the United States.
Avoiding risk factors, identifying and removing precancerous lesions through screening, and detecting cancer at an early stage when treatment is more effective will prevent hundreds of thousands of cancers from occurring and dying.
03BJ Haem: Family clustering of early-onset hematological malignancies A few days ago, BJ Haem published a study online.
A significant increase in standardized incidence rate (SIR) indicates that there is a common cause in some families.
In early-onset hematological malignancies Tumor (HM) patients should pay attention to this clinical situation during treatment.
Article release screenshots Few population-based studies of HM family clustering specifically focus on early-onset HM.
The study evaluated individuals diagnosed with early-onset HM and their relatives Hodgkin’s lymphoma (HL), non-Hodgkin’s lymphoma (NHL), acute lymphoblastic leukemia/lymphoma (ALL/LBL) and acute myeloid cells SIR and cumulative risk of AML.
The study identified 8,791 patients ≤40 years of age who were diagnosed with primary HM from the Finnish Cancer Registry between 1970 and 2012, and retrieved 75,774 family members from the population register.
Among the most common children, adolescents, and young adults (AYA) with HM, the SIR of their first-degree relatives, HM, is elevated.
Among them, HL (SIR: 9.
09; 95% CI: 5.
55-14.
04) and AML (SIR: 8.
29, 95% CI: 1.
00-29.
96) have the highest risk.
The cumulative risk of HL is also highest for siblings under 40 (0.
92% vs 0.
11%).
04CLIN CANCER RES: Afatinib VS Afatinib + Cetuximab as the first-line treatment option for EGFR-mutant non-small cell lung cancer (NSCLC) patients (IFCT-1503 ACE-Lung) Phase II randomized trial RES published a study online that showed that for untreated patients with advanced EGFR-mutant non-small cell lung cancer (NSCLC), there is no need for further studies on the addition of cetuximab to afatinib treatment.
Article release screenshots Using tyrosine kinase inhibitors and monoclonal antibodies to double inhibition of EGFR may be a new treatment strategy for non-small cell lung cancer (NSCLC).
We evaluated the efficacy and toxicity of afatinib vs afatinib+cetuximab in the first-line treatment of advanced EGFR-mutant NSCLC.
In this non-comparative, randomized, open-label, phase II study, patients with stage III/IV EGFR-positive NSCLC were randomly assigned (1:1) to receive afatinib (A) or afatinib + cetuximab Anti-(A+C) treatment.
Group A: Afatinib 40 mg orally once a day; Group A+C: Cetuximab 250 mg/m2 was injected intravenously on the 15th day of the first cycle, and then 500 mg/m2 every 2 weeks It is given once for 6 months.
The primary endpoint is the treatment failure rate at 9 months.
In addition, exploratory analysis of EGFR circulating tumor DNA in plasma was also carried out.
From June 2016 to November 2018, 59 patients were enrolled in group A and 58 patients were enrolled in group A+C.
The trial was terminated early due to invalidity analysis.
At 9 months, the proportion of patients without treatment failure in the two groups was similar (59.
3% in group A vs 64.
9% in group A+C), and the median time to treatment failure (TTF) was 11.
1 months (95%CI: 8.
5-14.
1) And 12.
9 (95%CI: 9.
2-14.
5) months.
The other endpoints [Progress-Free Survival (PFS) and Overall Survival (OS)] showed no significant improvement in combination therapy.
Adverse events (≥Grade 3) in the A+C group increased slightly.
The allele frequencies of EGFR gene mutations in circulating tumor DNA at baseline in both treatment groups were associated with shortening of PFS.
Reference: [1] http://news.
bioon.
com/article/6787384.
html[2] American Cancer Society.
Cancer Prevention & Early Detection Facts & Figures, 2021-2022.
Atlanta: American Cancer Society; 2021.
[ 3] Rönkkö R, Hirvonen E, Malila N, Kilpivaara O, Wartiovaara-Kautto U, Pitkäniemi J.
Familial aggregation of early-onset haematological malignancies.
Br J Haematol.
2021 May 18.
doi: 10.
1111/bjh.
17477.
Epub ahead of print.
[4] Cortot AB, Madroszyk-Flandin A, Giroux Leprieur E, Molinier O, Quoix E, Berard H, Otto J, Rault I, Moro-Sibilot D, Raimbourg J, Amour E, Morin F, Hureaux J, Moreau L, Debieuvre D, Morel H, Renault A, Pichon E, Huret B, Charpentier S, Denis MG, Cadranel J.
First-line Afatinib plus Cetuximab for EGFR-mutant Non-small-cell Lung Cancer: Results from the Randomized Phase 2 IFCT-1503 ACE-Lung Study.
Clin Cancer Res.
2021 May 24: clincanres.
4604.
2020.
doi:10.
1158/1078-0432.
CCR-20-4604.
Epub ahead of print.
